Q-omics provides the consensus-scored DNAJC25-GNG10 profile across patient tissues and cancer cell-line models. DNAJC25-GNG10 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, DNAJC25-GNG10 is differentially expressed in 3, with the highest sampling consensus in LUAD. Additionally, DNAJC25-GNG10 RNA expression shows 6,552 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KICH, LUAD, and ACC as cancer lineages where DNAJC25-GNG10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DNAJC25-GNG10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DNAJC25-GNG10 survival associations across molecular data types. DNAJC25-GNG10 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DNAJC25-GNG10 RNA expression–survival associations across cancer types. High DNAJC25-GNG10 expression shows unfavorable associations in KICH, DLBC, LUAD and COAD, but favorable associations in PAAD and LUSC. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for DNAJC25-GNG10 RNA expression.
This table summarizes DNAJC25-GNG10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for DNAJC25-GNG10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DNAJC25-GNG10 shows higher tumor expression in LUAD, STAD and LIHC. The LUAD box plot shows higher DNAJC25-GNG10 RNA expression in tumor versus normal tissue (log2 FC = +0.041, t-test p = .012).
This table shows molecular features associated with DNAJC25-GNG10 in patient tissues and cancer cell lines. In patient samples, DNAJC25-GNG10 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, DNAJC25-GNG10 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT.
